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drug-eluting stent implantation
Hyung Joon Joo1, Cheol Woong Yu1, Rak Kyong Choi2, Jin Sik Park2,
Hyun Jong Lee3, Je Sang Kim2, Young Jin Choi2, Jae Hyoung Park1, Soon Jun Hong1,
Do-Sun Lim1
1Korea University Anam Hospital, Seoul, Korea, Republic of, 2Sejong General
Hospital, Bucheon, Kyeong-gi, 3Sejong general hospital, Bucheon, Kyeong-gi
Background: There has been a few data about the long-term clinical outcomes of
patients with coronary artery aneurysm (CAA) after drug-eluting stent (DES) im-
plantation. The aim of study is to explore the long-term clinical outcomes of CAA
after DES implantation.
Methods: A total of 94 patients with CAA (105 lesions) after DES implantation (CAA
group) were retrospectively compared with 523 patients (523 lesions) who underwent
DES implantation (non-CAA group). The primary end point was deﬁned as major
adverse cardiac events (MACE) : composites of all-cause death, non-fatal myocardial
infarction (MI), or target vessel revascularization (TVR). Propensity score-matching
analysis was performed in 85 patient pairs.
Results: CAA group had higher incidence of hypertension (64.9% vs. 53.2%,
p¼0.03), lower incidence of dyslipidemia (55.3% vs. 67.2%, p¼0.02), andB28 JACC Vol 64/11/Suppl B j Septemblonger duration of dual antiplatelet therapy (1323860day vs. 767636day,
p< 0.01). Procedural data showed that CAA group had more 1st generation DES
(95.2% vs. 51.4%, p< 0.01), lower stent size (3.000.33mm vs. 3.190.44mm,
p< 0.01) and longer stent length (38.218.5mm vs. 31.717.6mm, p< 0.01).
During a median follow-up period of 860802 days, CAA group had signiﬁ-
cantly higher incidence of MACE (34.0% vs. 7.7%, p< 0.01), which was mainly
driven by non-fatal MI (13.8% vs. 0.76%, p< 0.01) and TVR (28.7% vs. 1.53%,
p< 0.01). The incidence of stent thrombosis was also higher in CAA group
(10.64% vs. 0.19%, p< 0.01). Cox proportional hazard analysis demonstrated
that independent predictors for MACE were CAA (hazard ratio [HR]: 2.53,
[95% conﬁdence interval (CI): 1.528-4.186]), stent number (HR: 1.62, 95% CI:
1.002-2.626), and the prior coronary artery bypass (HR: 4.84, 95% CI: 1.464-
16.029). After propensity-score matching, CAA group still had signiﬁcantly
higher incidence of MACE (32.9% vs. 5.8%, p< 0.01), non-fatal MI (14.1% vs.
0%, p< 0.01), TVR (27% vs. 1.2%, p< 0.01), and stent thrombosis (10.6% vs.
0%, p< 0.01).
Conclusions: CAA group had worse long-term clinical outcomes than non-CAA
group, especially by increase of stent thrombosis, non-fatal MI or TVR. Indeﬁnite use
of DAPT may be needed for CAA patients.
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Background: Elevations of cardiac troponin (cTn) over the upper reference limit
(URL) is a well known predictor of adverse prognosis in unstable coronary artery
disease (CAD). Novel more sensitive cTn assays have the potential for stratifying cTn
levels within the normal range also in patients with apparently stable CAD. The aim of
our study was to evaluate the prognostic value of preprocedural cTnI levels below the
URL, measured with a contemporary available sensitive assay, in stable CAD patients
treated with percutaneous coronary interventions (PCI).
Methods: In 1063 consecutive patients with normal baseline cTnI levels treated with
elective and angiographically successful PCI, we investigated the correlation between
pre-PCI cTnI levels and major clinical adverse events (median follow up of 3.0 years).
Results: Preprocedural cTnI levels were stratiﬁed into tertiles. When compared with
the lower, the upper tertile showed an increased long term risk of overall death (HR
3.17, 95% CI 1.62 to 6.21; P¼0.0001), cardiac death (HR 5.09, 95% CI 2.30 to 11.25;
P¼0.002), myocardial infarction (MI) (HR 2.34, 95% CI 1.45 to 3.76; P¼0.003) and
target vessel failure (TVF) (HR 1.91, 95% CI 1.28 to 2.84; P¼0.006). After adjust-
ment for clinical and angiographic ﬁndings, baseline cTnI level remained an inde-
pendent predictor of cardiac death, MI and TVF.
Conclusions: In a large single-centre population of stable CAD patients treated with
successful PCI, pre-procedural cTnI level, even if below the URL, resulted a strong
independent predictor of long term hard end points.
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Background: Beta-blocker therapy has been shown to beneﬁt in patients presenting
with acute coronary syndrome or left ventricular (LV) dysfunction. However, whether
beta-blockers provide a similar beneﬁt in stable coronary artery disease (SCAD) pa-
tients with normal LV function after percutaneous coronary intervention (PCI) is
unknown.
Methods: A population of 4,266 patients with SCAD with normal LV function who
were treated by PCI was evaluated. Among those, beta-blocker was prescribed in 2794
(65.5%) patients. Primary endpoint was the composite of death from any cause and
spontaneous myocardial infarction (MI).
Results: During the mean follow-up of 31.510.4 months, primary endpoint of
the composite of death and MI were occurred in 97 (3.5%) patients with beta-
blocker and 62 (4.2%) patients without beta-blocker, respectively. Unadjusted
hazard ratio (HR) for the primary end-points was 0.819 (95% CI 0.595 to 1.126,
p¼0.219); for death, 0.724 (95% CI, 0.510 to 1.028, p¼0.071); for MI, 1.136
(95% CI, 0.573 to 2.251, p¼0.700). After adjusting baseline characteristics,
adjusted HR was 0.802 (95% CI 0.577 to 1.116, p¼0.191) for the primary-
endpoint; 0.729 (95% CI 0.507 to 1.047, p¼0.087) for death; 1.124 (95% CI
0.562 to 2.248, p¼0.741) for MI.
Conclusions: In SCAD patients with normal LV function after PCI, beta-blocker was
not associated with signiﬁcant reduction of death or MI.er 13–17, 2014 j TCT Abstracts/Angioplasty Overview and Outcomes
Table. Parsimonious model with predictor variables and estimated odds-ratio
predicting BARC 1 or greater bleeding events.
Effect*
Odds
Ratio
Lower
Conﬁdence
Limit
Upper
Conﬁdence
Limit
Caucasian Race 2.85 2.14 3.79
Diabetes Mellitus 0.55 0.44 0.67
Female Sex 1.75 1.37 2.23
Warfarin therapy on admission 2.03 1.26 3.27
Use of Drug Eluting Stent 1.52 1.20 1.91
History of Chronic Lung Disease 1.66 1.20 2.28
Urgent PCI vs. Elective/Planned
PCI
0.77 0.62 0.94
Emergent PCI vs. Elective/Planned
PCI
1.02 0.56 1.87
Platelets (per 50,000 units/dl) 0.90 0.83 0.96
Body Mass Index (Kg/m2) per 5
unit increment
0.92 0.85 1.00
Current Smoker 0.79 0.61 1.02
Age (per 10 year increment) 0.91 0.83 1.01
Hemoglobin 13 to <15 vs.
Hemoglobin  15 (gm/dl)
1.19 0.94 1.51
Hemoglobin <13 vs. Hemoglobin
 15 (gm/dl)
1.13 0.86 1.50
STEMI 0.59 0.29 1.17
History of Peripheral Arterial
Disease
1.25 0.87 1.79
* We used Harrell’s backward selection strategy to select a parsimonious set of variables for
the ﬁnal model from a larger set of covariates selected a-priori. In this selection strategy,
variables with the smallest contribution to the model (by F-value) are sequentially eliminated
until further variable elimination leads to a greater than 5% loss in model prediction, as
compared with the initial fully adjusted model.
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Background: The use of drug-eluting stents necessitates prolonged dual antiplatelet
therapy after PCI, which increases patents’ risk for bleeding complications. However,
there are no models to predict long-term bleeding events in patients undergoing PCI.
Methods: A total of 3,128 PCI procedures in the multicenter PRISM study were
analyzed. Patient reported bleeding events were categorized by Bleeding Academic
Research Consortium (BARC) deﬁnitions; 0 (no-bleed), 1 (bleeding/bruising not
requiring treatment), 2 (bleeding that is actionable), or 3 (needing hospitalization/
transfusion). We used logistic regression to develop a model predicting BARC  1
bleeding. Discrimination and calibration were used to evaluate model performance. A
sensitivity analysis was performed for BARC 1 or greater bleeding events excluding
easy bruising.
Results: No bleeding and BARC 1, 2 and 3 bleeding were observed in 574
(18.4%); 2382 (76.2%); 114 (3.6%) and, 58 (1.8%) patients, respectively, at one
year. Compared with patients with no-bleeding, patients with BARC  1
bleeding were more often female (30 vs. 23%), and Caucasian (94 vs. 83%), and
had a higher incidence of DES implantation (83 vs. 76%) and warfarin therapy
(7.4 vs. 3.9%) and less diabetes (31 vs. 45%; p-value < 0.01 for all compari-
sons). The model discriminated well (c-statistic of 0.672), as did a more parsi-
monious model (table; c-statistic ¼ 0.669). There was excellent calibration
(Hosmer-Lemeshow; p¼0.915), indicating good ﬁt. Only easy bruising was
observed in 602 (19.2%) patients, and sensitivity analyses excluding easy
bruising from BARC  1 bleeding had slightly lower discrimination (c-statistic
0.621).
Covariates eligible for inclusion in the model: Age, sex, race, high school educa-
tion, no insurance, current smoker, history of peripheral arterial disease, history of
diabetes mellitus, history of chronic kidney disease, history of myocardial infarction,
prior PCI, history of heart failure, history of prior stroke, history of hypertension,
history of dyslipidemia,history of chronic lung disease, Chronic Kidney Disease (GFR
60, 30-59, <30 and dialysis), hemoglobin, platelet count, PCI indication (urgent,
emergent or elective/planned), STEMI vs. other indication presentation for PCI, use of
drug eluting stent, warfarin on admission, access site (radial, femoral or brachial) and
cardiac arrest on arrival.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AngioplasConclusions: A large proportion of patients report bleeding complications after
PCI, and these can be predicted by pre-procedural characteristics. Estimates of
bleeding risk may help support shared decision-making with respect to stent
selection during PCI.
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Background: Complete revascularization (CR) is considered as a goal for percuta-
neous coronary intervention (PCI). Previous studies have proved that achieving CR is
beneﬁcial compared to incomplete CR. However there has been no research about the
long term outcome within CR patients.
Methods: From patients enrolled in the Efﬁcacy of Xience/Promus versus Cypher in
rEducing Late Loss after stENTing (EXCELLENT) registry, the SYNTAX score was
checked before and after PCI. The primary clinical outcome was 3-year patient-ori-
ented composite endpoint (POCE), which was a composite of all cause death, any
myocardial infarction, and any revascularization. Secondary outcomes were the in-
dividual components of 3-year POCE and 3-year target lesion failure (TLF). For
calculation of the clinical SS, the SS was multiplied with the value of the ‘Age,
Creatinine, and Ejection Fraction’ score.
Results: Among 5,102 patients from the EXCELLENT registry, 2,112 patients
achieved CR by PCI. 3-year POCE was less common in CR patients (10.0% vs.
16.9%, p< 0.001) and CR was an independent predictor of adverse outcomes
(Hazard ratio (HR) 1.326, 95% Conﬁdence Interval (CI) 1.108-1.587, p¼0.002).
Patients who achieved CR were divided into 3 groups, according to the pre-PCI
SYNTAX score (SS); 1low-SS< 6: 771 patients, 6mid-SS< 10: 692 patients, and
high-SS10: 649 patients. 3-year POCE increased signiﬁcantly along with increasing
baseline SS tertiles (7.5% vs. 8.4% vs. 14.8%, p< 0.001) and secondary outcomes
also showed similar tendency. Multivariate analysis showed that baseline SS was an
independent predictor of 3-year POCE (HR 1.032, 95% CI 1.011-1.053, p¼0.003 perty Overview and Outcomes B29
